Stem Cell Mobilizer and Immunosuppressive Agent Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for down-regulating molecular pathways to treat inflammation, allograft rejection, autoimmune diseases, ischemia, reperfusion injury, neurodegenerative diseases, inflammatory pain, steatohepatitis, anti-thrombosis, anti-aging, anti-fibrosis, and anti-cancer, as well as up-regulating interferon alpha response and heme metabolism pathways.
Innovation Solution
Administration of a pharmaceutical composition comprising a stem cell mobilizer, such as AMD3100, and an immunosuppressive agent or non-immunosuppressive FK binding protein ligand, like Tacrolimus, at sub-immunosuppressive doses to mobilize stem and immune cells, down-regulate specific pathways, and up-regulate interferon alpha and heme metabolism pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If immunosuppressive agents are administered at standard doses to down-regulate inflammatory and autoimmune pathways, then inflammation and autoimmune responses are suppressed, but immunosuppression occurs leading to reduced antiviral and anti-cancer responses
Solution Approach 1:
The patent applies parameter changes by administering immunosuppressive agents at reduced doses (below standard immunosuppressive thresholds) and using stem cell mobilizers at optimized concentrations (e.g., AMD3100 at 0.05-0.2 mg/kg). This dosage optimization allows down-regulation of inflammatory pathways while preserving immune surveillance functions for antiviral and anti-cancer responses
Solution Approach 2:
The treatment regimen is segmented into sequential phases: initial stem cell mobilization phase followed by immunosuppressive agent administration phase. This temporal segmentation allows different mechanisms to operate at different times - mobilization first to prepare regenerative capacity, then immunosuppression to control inflammation without completely suppressing immune function
2Productivity
If stem cell mobilizers are administered to mobilize stem and immune cells, then tissue repair and regeneration are enhanced, but pathway regulation precision is reduced
Solution Approach 1:
The patent uses specific stem cell mobilizers (AMD3100, plerixafor) as intermediaries that selectively target CXCR4 receptors on stem cells to induce mobilization. This specific receptor-ligand interaction provides precision in cell mobilization while the subsequent administration of immunosuppressive agents provides precision in pathway regulation, combining both benefits
Solution Approach 2:
The patent merges two distinct therapeutic approaches - stem cell mobilization and immunosuppression - into a single coordinated treatment regimen. The combination therapy achieves both enhanced tissue repair (from mobilization) and precise pathway regulation (from immunosuppression), with the added benefit that mobilized stem cells may differentiate to replace damaged tissues
Data Source
AI summary
The present disclosure provides methods for treating various diseases or disorders, down-regulating and up-regulating various pathways and mobilizing stem and/or immune cells in a patient, comprising administering a pharmaceutical composition to a subject. In certain embodiments, the pharmaceutical composition comprises (a) a stem cell mobilizer and (b) an immunosuppressive agent or non-immunosuppressive FK binding protein ligand in a low or sub-immunosuppressive dose. The methods of the disclosure can comprise administering the pharmaceutical composition by routes and dosing regimens, as disclosed herein.